Data were retrospectively collected from 188 consecutive patients between 1984 and 2009. Overall survival (OS), progression-free survival (PFS), and risk factors were analyzed in patients classified into 3 groups (group A: complete resection, group B: reduction surgery, and group C: drainage or exploratory laparotomy).
In group A (n = 119), the 10-, 15-, and 20-year OS was 98.9 % . In group B (n = 63), the 10-, 15-, and 20-year OS was 97.1 % , 92.8 % , and 61.9 % . In group C (n = 6), the 10- and 15-year OS was 50.0 % and 33.3 % . Patients in groups A and B had better prognoses than those in group C (p < 0.001). In group A, the 10-, 15-, and 20-year PFS was 96.5 % , 94.4 % , and 94.4 % . In group B, the 10-, 15-, and 20-year PFS was 87.1 % , 71.6 % , and 61.4 % . In group C, the 10- and 15-year PFS was 50.0 % and 33.3 % . Patients in group A had better PFS than those in groups B and C (p < 0.001). Curability was the only independent factor for both OS and PFS by multivariate analysis.
Although the most effective therapy for AE is complete resection, a better prognosis can be achieved by reduction surgery and/or adjuvant albendazole therapy for patients with AE that cannot be completely resected.